dc.contributor.advisor |
|
|
dc.contributor.author |
Birkholtz, Lyn-Marie
|
|
dc.contributor.author |
Coetzer, Theresa L.
|
|
dc.contributor.author |
Mancama, Dalu
|
|
dc.contributor.author |
Leroy, Didier
|
|
dc.contributor.author |
Alano, Pietro
|
|
dc.date.accessioned |
2016-11-14T06:42:19Z |
|
dc.date.issued |
2016-09 |
|
dc.description.abstract |
The ability to target human-mosquito parasite transmission challenges global
malaria elimination. However, it is not obvious what a transmission-blocking
drug will look like; should it 1) target only parasite transmission stages; 2) be
combined with a partner drug killing the pathogenic asexual stages or 3) kill
both the sexual and asexual blood stages, preferably displaying
polypharmacology. The development of transmission-blocking anti-malarials
requires objective analyses of the current strategies. Here, pertinent issues
and unanswered questions regarding the target candidate profile of a transmission-blocking compound, and its role in malaria elimination strategies
are highlighted and novel perspectives proposed. The essential role of a test
cascade that integrates screening and validation strategies to identify next
generation transmission-blocking anti-malarials is emphasised. |
en_ZA |
dc.description.department |
Biochemistry |
en_ZA |
dc.description.embargo |
2017-09-30 |
|
dc.description.librarian |
hb2016 |
en_ZA |
dc.description.sponsorship |
Koen Dechering (TROPIQ, The Netherlands), Francesco Silvestrini (Istituto
Superiore di Sanità, Rome, Italy), Sarah D’Alessandro and Donatella
Taramelli (University of Milan, Italy), Robert Sauerwein (University of
Nijmegen, The Netherlands) and Omar Vandal (The Bill & Melinda Gates
Foundation) are acknowledged for their contributions towards the screening
cascade, which they developed in the course of the Bill and Melinda Gates
Foundation Project OPP1040394 ‘Gametocyte Assays for Malaria (GAM) for
novel transmission blocking drugs’, coordinated by PA. The South African
Transmission-blocking Consortium is funded by the Medical Research Council
of South Africa as a Strategic Health Innovation Partnership (MRC SHIP)
project. |
en_ZA |
dc.description.uri |
http://www.journals.elsevier.com/trends-in-parasitology |
en_ZA |
dc.identifier.citation |
Birkholtz, LM, Coetzer, TL, Mancama, D, Leroy, D & Alano, P 2016, 'Discovering new transmission-blocking antimalarial compounds : challenges and opportunities', Trends in Parasitology, vol. 32, no. 9, pp. 669-681. |
en_ZA |
dc.identifier.issn |
1471-4922 (print) |
|
dc.identifier.issn |
1471-5007 (online) |
|
dc.identifier.other |
10.1016/j.pt.2016.04.017 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/57949 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Elsevier |
en_ZA |
dc.rights |
© 2016 Elsevier Ltd. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in Trends in Parasitology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in Trends in Parasitology, vol. 32, no. 9, pp. 669-681, 2016. doi : 10.1016/j.pt.2016.04.017. |
en_ZA |
dc.subject |
Drug discovery |
en_ZA |
dc.subject |
Elimination |
en_ZA |
dc.subject |
Gametocytes |
en_ZA |
dc.subject |
Malaria |
en_ZA |
dc.subject |
Transmission |
en_ZA |
dc.title |
Discovering new transmission-blocking antimalarial compounds : challenges and opportunities |
en_ZA |
dc.type |
Postprint Article |
en_ZA |